CN102264752A - 苯烷基-咪唑-二膦酸化合物 - Google Patents

苯烷基-咪唑-二膦酸化合物 Download PDF

Info

Publication number
CN102264752A
CN102264752A CN2009801522256A CN200980152225A CN102264752A CN 102264752 A CN102264752 A CN 102264752A CN 2009801522256 A CN2009801522256 A CN 2009801522256A CN 200980152225 A CN200980152225 A CN 200980152225A CN 102264752 A CN102264752 A CN 102264752A
Authority
CN
China
Prior art keywords
phenyl
formula
compound
alkyl
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801522256A
Other languages
English (en)
Chinese (zh)
Inventor
S·科泰斯塔
W·延克
J-M·龙多
S·韦勒
L·维德勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN102264752A publication Critical patent/CN102264752A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2009801522256A 2008-12-23 2009-12-21 苯烷基-咪唑-二膦酸化合物 Pending CN102264752A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08172824.8 2008-12-23
EP08172824 2008-12-23
US14275509P 2009-01-06 2009-01-06
US61/142,755 2009-01-06
PCT/EP2009/067679 WO2010076258A1 (en) 2008-12-23 2009-12-21 Phenylalkyl-imidazole-bisphosphonate compounds

Publications (1)

Publication Number Publication Date
CN102264752A true CN102264752A (zh) 2011-11-30

Family

ID=40595694

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801522256A Pending CN102264752A (zh) 2008-12-23 2009-12-21 苯烷基-咪唑-二膦酸化合物

Country Status (11)

Country Link
US (1) US20110257131A1 (https=)
EP (1) EP2382223A1 (https=)
JP (1) JP2012513443A (https=)
KR (1) KR20110110219A (https=)
CN (1) CN102264752A (https=)
AU (1) AU2009334889A1 (https=)
BR (1) BRPI0924887A2 (https=)
CA (1) CA2746612A1 (https=)
EA (1) EA201100964A1 (https=)
MX (1) MX2011006605A (https=)
WO (1) WO2010076258A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109608492A (zh) * 2018-12-19 2019-04-12 深圳市第二人民医院 一种用于骨质疏松的二膦酸化合物及其制备方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273357B2 (en) 2011-04-04 2016-03-01 The Trustees Of Columbia University In The City Of New York Pharmacogenetic test anti-resorptive therapy-associated osteonecrosis of the jaw
WO2016081281A1 (en) * 2014-11-17 2016-05-26 Salk Institute For Biological Studies Lipophilic bisphosphonates and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3428524A1 (de) * 1984-08-02 1986-02-13 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3626058A1 (de) * 1986-08-01 1988-02-11 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
ES2038692T4 (es) * 1986-11-21 2012-02-10 Novartis Ag Procedimiento para la obtencion de acidos alcanodifosfonicos substituidos.
JPH05148279A (ja) * 1991-08-01 1993-06-15 Kaken Pharmaceut Co Ltd ビスホスホン酸誘導体
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
US8012949B2 (en) * 2004-10-08 2011-09-06 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
US7687482B2 (en) * 2006-03-17 2010-03-30 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods
EP1802641B8 (en) * 2004-10-08 2012-03-07 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
US20080255366A1 (en) * 2005-09-12 2008-10-16 Dr. Reddy's Laboratories Limited Crystalline Trihydrate of Zoledronic Acid
AR063121A1 (es) * 2006-10-05 2008-12-30 Novartis Ag Composicion farmaceutica

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109608492A (zh) * 2018-12-19 2019-04-12 深圳市第二人民医院 一种用于骨质疏松的二膦酸化合物及其制备方法
CN109608492B (zh) * 2018-12-19 2021-02-09 深圳市第二人民医院 一种用于骨质疏松的二膦酸化合物及其制备方法

Also Published As

Publication number Publication date
AU2009334889A1 (en) 2011-06-30
CA2746612A1 (en) 2010-07-08
EA201100964A1 (ru) 2012-02-28
WO2010076258A1 (en) 2010-07-08
BRPI0924887A2 (pt) 2015-07-07
EP2382223A1 (en) 2011-11-02
KR20110110219A (ko) 2011-10-06
US20110257131A1 (en) 2011-10-20
MX2011006605A (es) 2011-06-30
JP2012513443A (ja) 2012-06-14

Similar Documents

Publication Publication Date Title
JP5244917B2 (ja) Ｃ２−ｃ５−アルキル−イミダゾール−ビスホスホネート類
US7687482B2 (en) Bisphosphonate compounds and methods
US7745422B2 (en) Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
US8012949B2 (en) Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
CA2682694A1 (en) Bisphosphonate compounds and methods with enhanced potency for multiple targets including fpps, ggpps, and dpps
NZ246152A (en) 3-(aminoalkyl- and azaheterocyclylalkyl)-2-phosphonosuccinic acid derivatives and pharmaceutical compositions
CN102264752A (zh) 苯烷基-咪唑-二膦酸化合物
WO2009029849A1 (en) Prodrugs and conjugates of prenylation inhibitors
HU208701B (en) Process for producing new methylene bisphosphonic acid derivatives and medical preparatives containing them as active agent
ZA200104443B (en) Organo-phosphorus compounds and their utilization.
CN101605802A (zh) 双膦酸及其盐的制备方法
CA2352317A1 (en) Amino alkylphosphonic acid derivatives and their use in treating infections
Chmielewska et al. Reaction of benzolactams with triethyl phosphite prompted by phosphoryl chloride affords benzoannulated monophosphonates instead of expected bisphoshonates
CA2138127C (en) New acyclic amidine group-containing diphosphonic acid derivatives, processes for their preparation and medicaments containing these compounds
JPH0656857A (ja) アミジンおよび新規のアミジンを含む医薬組成物
GB2113688A (en) Diphosphonic acid derivatives, process for their preparation and pharmaceutical preparations containing them.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20111130